Journal of Commercial Biotechnology welcomes new editorial advisory board members

The Journal of Commercial Biotechnology is proud to announce the addition of two esteemed industry experts to its advisory board.

The new editorial board members are:

  • Ananda Mohan Chakrabarty, distinguished university professor at the University of Illinois at Chicago and noted for his genetically modified Pseudomonas bacteria that became the first genetically-engineered organism to gain a US patent as a result of the Supreme Court decision in Diamond vs. Chakrabarty. He is the co-founder of two companies, CDG Therapeutics Inc. in Chicago and Amrita Therapeutics in India.
  • Meir Perez Pugatch, Managing Director Pugatch Consilium; Chair, Division of Health Systems Administration, School of Public Health, University of Haifa, Israel

These esteemed individuals complement the existing editorial advisory board, which includes:

  • Mark Ahn, Principal, Pukana Partners, Ltd., USA, United States
  • John Avellanet, Cerulean Associates LLC, United States
  • Boris Bogdan, Partner, Avance, Basel GmbH, Switzerland
  • Arthur Boni, John R. Thorne Chair of Entrepreneurship; Associate Teaching Professor of Entrepreneurship; and Director, Donald H. Jones Center for Entrepreneurship, Tepper School of Business, Carnegie Mellon University, United States
  • Walter Bratic, Managing Director, Overmont Consulting LLC, United States
  • G. Steven Burrill, Chief Executive Officer, Burrill & Company, United States
  • Steven Casper, Henry E. Riggs Professor of Management, Keck Graduate Institute of Applied Life Sciences, United States
  • Vijay Chandra, Chairman & CEO, Strand Life Sciences Pvt Ltd, India and Consulting Professor, ISL/EE, Stanford University, United States
  • James Class, Director, Global Public Policy, Merck, United States
  • Jeremy Laurence Curnock Cook, Executive Chairman, Bioscience Managers Limited, United Kingdom
  • Iraj Daizadeh, Senior Manager, Amgen Inc, United States
  • Mitch DeKoven, Director – Reimbursement and Market Access, Health Economics & Outcomes Research, IMS Health, United States
  • Spencer G. Feldman, Shareholder, Greenberg Traurig, United States
  • Sharon Finch, Director, Medius Associates, United Kingdom
  • Hernan Garrido-Lecca, Chairman and CEO Bioinvest; Professor of Economics and Public Policy, Universidad de San Martín de Porres, Lima Peru and Former Minister of Health, Peru
  • Gerald S. Graham, Business and Management Consultant, Graham Consulting Group, United States
  • Dave Jensen, Managing Director, CareerTrax Inc., United States
  • Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development and Professor of Medicine, Tufts University School of Medicine, United States
  • John Khong, Owner, Niche Medical, J & M Technologies, Cell Sciences; Adjunct faculty, LKC Business School, Singapore management University, Singapore
  • Edward L. Korwek, Partner, Hogan Lovells, United States
  • Thomas J. Kowalski, Attorney at Law, Vedder Price P.C., United States
  • Leonard Lerer, Sudarskis & Partners, United Arab Emirates
  • Weijun Li, Senior Research Scientist, Global Biological Development, Bayer HealthCare Pharmaceuticals, United States
  • Bryan A. Liang, Professor of Anesthesiology & Director San Diego Center for Patient Safety, University of California San Diego School of Medicine; Professor of Law & Executive Director, Institute of Health Law Studies, California Western School of Law, United States
  • Kate Lynch, CEO, Generic Medicines Industry Association (GMiA), Australia
  • Barry Marenberg, Chief Intellectual Property Strategist, BJM BioPat Solutions, United States
  • Henry I. Miller, Senior Research Fellow of Scientific Philosophy & Public Policy, Hoover Institution, Stanford University, United States
  • Stefan Michael Miller, Associate, Dechert LLP, United States
  • Sudha Nair, Director, Global Business Development, Apotex Fermentation Inc., Canada
  • Robin Nott, Chair of the Laws Committee, Licensing Executives Society Britain and Ireland, United Kingdom
  • Meir Perez Pugatch, Chair Division of Health Systems Administration, School of Public Health, University of Haifa; Managing Director Pugatch Consilium, Israel
  • Rebecca Robins, Director, Europe, Business Development, Interbrand Wood Healthcare, United Kingdom
  • Anthony J Russo, Chairman and CEO, Russo Partners, United States
  • Stephen M. Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurial Programs and Venture Partner, Burrill & Company, United States
  • Simon Shohet, Practice Director, Pope Woodhead & Associates Ltd, United Kingdom
  • Grant Skrepenk, Assistant Professor, The University of Arizona College of Pharmacy and Investigator, Center for Health Outcomes and PharmacoEconomic Research, United States
  • Anthony Stevens, Director, Medical Options, United Kingdom
  • Philip Neal Sussman, Managing Partner, The Channel Group LLC, United States
  • Michael Vitale, Director of Commercialisation, Monash Asia-Pacific Centre for Science and Wealth Creation, Monash University, Australia
  • Stan Yakatan, Chairman, Katan Associates, United States

For more information, see the Journal of Commercial Biotechnology at

   No Comments yet

  1. stan yakatan
      November 29, 2011

    nice board let do something together in 2012

  2. stan yakatan
      November 29, 2011

    nice board lets do something together in 2012